Symposium on regenerative medicineBreakthroughs in Cell Therapy for Heart Disease: Focus on Cardiosphere-Derived Cells
Section snippets
Breakthrough 1: Establishment of Safety With Intracoronary Delivery
Skeletal myoblasts were the first cells to be applied to heart disease, on the logical premise that autologous satellite cells might develop into mature contractile units when implanted ectopically into the diseased heart.6 The paradigm involved harvesting skeletal muscle biopsy specimens from patients with HF who were to undergo elective cardiac surgery; myoblasts would be grown ex vivo and then reimplanted by direct intramyocardial injection at the time of surgery. Despite early enthusiasm
Breakthrough 2: Finding of Therapeutic Regeneration
Regeneration is defined as “regrowth of lost or destroyed parts or organs.”19 Although human BMMC studies have reported reductions in scar size,20 the effect is solely on scar mass with no reciprocal increase in viable myocardium. Thus, such changes report a decrease in the extent of injury but not regrowth of destroyed parts. During the past 10 years, my laboratory has developed cardiosphere-derived cells (CDCs) as a candidate cell type for regenerative therapy after MI.21 These heart-derived
Breakthrough 3: The Rise of Allogeneic Cell Therapy
During the first decade of cell therapy for heart disease, most clinical trials were conducted using autologous cells. This approach has the advantage that it avoids immunologic rejection, but autologous therapy requires patient-specific tissue harvesting, cell processing, and quality control, imposing significant risk, expense, and inflexibility with regard to the timing of treatment. In addition, cell efficacy may vary with donor age and comorbidities. The use of allogeneic cells, if safe and
Breakthrough 4: Increasing Mechanistic Insights
The guiding principle underlying the use of stem cells to achieve regeneration is the idea that injected cells will engraft, proliferate, and differentiate, thereby repopulating the injured heart. However, in many published studies, cell transplantation produces beneficial effects despite poor retention and minimal long-term survival of transplanted cells.31 How can transient, paltry short-term cell survival suffice to produce lasting benefits? Multiple lines of evidence now indicate that most
Breakthrough 5: Glimmers of Clinical Efficacy
The BMMC experience has been notable for little evidence of benefit in surrogate end points, namely, an inconsistency of improvements in ejection fraction and scar size and the absence of rigorous evidence of genuine myocardial regeneration. Nevertheless, it is intriguing that significant benefits on clinical end points have been reported. The Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction study reported favorable clinical outcomes associated with
Breakthrough 6: Progression to Phase 2 and 3 Studies
All too often in cell therapy, as in many other fields, promising early-phase trial results fail to be confirmed in larger studies.51 Well-powered and rigorously designed (randomized, placebo-controlled, double-blind) large-scale clinical trials with long-term follow-up, focusing on hard clinical end points, are mandatory to determine whether the changes in surrogate end points (eg, scar size, ventricular volumes, and ejection fraction) are consistent and whether they translate into increased
Conclusion
In the past several years, we have progressed from a profusion of hype to the point of having a solid basis for moving forward. With the good fortune of prevalent safety to date, we have managed to avoid the sort of debacle that derailed gene therapy for more than a decade.53 The evidence that therapeutic regeneration is possible, in a setting where conventional wisdom teaches that scar is irreversible, catapults the field onto a new plane yet to be achieved by any other treatment approach. The
References (55)
- et al.
Myoblast transplantation for heart failure
Lancet
(2001) - et al.
Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial
Lancet
(2011) - et al.
Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial
Lancet
(2012) - et al.
Intracoronary cardiosphere-derived cells after myocardial infarction: evidence for therapeutic regeneration in the final 1-year results of the CADUCEUS trial
J Am Coll Cardiol
(2014) - et al.
Heart to heart: cardiospheres for myocardial regeneration
Heart Rhythm
(2012) - et al.
Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial
Lancet
(2006) - et al.
Controlled delivery of basic fibroblast growth factor promotes human cardiosphere-derived cell engraftment to enhance cardiac repair for chronic myocardial infarction
J Am Coll Cardiol
(2008) - et al.
Intramyocardial injection of autologous cardiospheres or cardiosphere-derived cells preserves function and minimizes adverse ventricular remodeling in pigs with heart failure post-myocardial infarction
J Am Coll Cardiol
(2011) - et al.
Allogeneic cardiospheres safely boost cardiac function and attenuate adverse remodeling after myocardial infarction in immunologically mismatched rat strains
J Am Coll Cardiol
(2013) - et al.
Intracoronary autologous bone marrow stem cells transfer for patients with acute myocardial infarction: a meta-analysis of randomised controlled trials
Int J Cardiol
(2009)
Comparison of myocardial infarct size assessed with contrast-enhanced magnetic resonance imaging and left ventricular function and volumes to predict mortality in patients with healed myocardial infarction
Am J Cardiol
Promise of blood- and bone marrow-derived stem cell transplantation for functional cardiac repair: putting it in perspective with existing therapy
J Am Coll Cardiol
The hazards of randomized phase II trials
Ann Oncol
Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics
J Am Coll Cardiol
Heart disease and stroke statistics–2013 update: a report from the American Heart Association
Circulation
Third universal definition of myocardial infarction
Nat Rev Cardiol
Heart failure after acute myocardial infarction: a lost battle in the war on heart failure?
Circulation
Concise review: heart regeneration and the role of cardiac stem cells
Stem Cells Transl Med
The stuttering progress of cell therapy for heart disease
Clin Pharmacol Ther
The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation
Circulation
Intracoronary, human autologous stem cell transplantation for myocardial regeneration following myocardial infarction
Dtsch Med Wochenschr
Mixed results for bone marrow–derived cell therapy for ischemic heart disease
JAMA
Heparin disrupts the CXCR4/SDF-1 axis and impairs the functional capacity of bone marrow-derived mononuclear cells used for cardiovascular repair
Circ Res
Impact of timing on efficacy and safety of intracoronary autologous bone marrow stem cells transplantation in acute myocardial infarction: a pooled subgroup analysis of randomized controlled trials
Clin Cardiol
Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice
Circ Res
A highly sensitive and accurate method to quantify absolute numbers of c-kit+ cardiac stem cells following transplantation in mice
Basic Res Cardiol
Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells
Circulation
Cited by (0)
Grant Support: Work in Dr Marbán’s laboratory is funded by National Institute of Health grant R01 HL083109, US Department of Defense grant CSR205330/221349, and California Institute for Regenerative Medicine grant RB4-06215.
Potential Competing Interests: Dr Marbán is founder of, is unpaid adviser to, and owns equity in Capricor Therapeutics.
Individual reprints of this article and a bound reprint of the entire Symposium on Regenerative Medicine will be available for purchase from our website www.mayoclinicproceedings.org.
The Symposium on Regenerative Medicine will continue in an upcoming issue.